A statin in the treatment of heart failure?: Controlled rosuvastatin multinational study in heart failure (CORONA):: Study design and baseline characteristics
A statin in the treatment of heart failure?: Controlled rosuvastatin multinational study in heart failure (CORONA):: Study design and baseline characteristics
复制标题
DOI：
10.1016/j.ejheart.2005.09.005
复制
发表时间：
2005-10-01
影响因子：
18.2
通讯作者：
Wikstrand, J
中科院分区：
文献类型：
--
作者：
Kjekshus, J;Dunselman, P;Wikstrand, J
背景资料：既往关于他汀类药物的前瞻性结局研究未提供任何关于心力衰竭患者获益-风险的指导。目的：主要目的是确定瑞舒伐他汀（10 mg）是否能降低心血管死亡率、非致死性心肌梗死或非致死性卒中（至首次事件发生时间）的联合终点。第一个次要终点是全因mortality.Methods：CORONA是一项随机、双盲、安慰剂对照试验。简言之，男性和女性，年龄≥ 60岁，患有缺血性病因和射血分数的慢性症状性收缩性心力衰竭
Background: Previous prospective outcome studies of statins have not provided any guidance on benefit-risk in patients with heart failure.Aim: The primary objective is to determine whether rosuvastatin (10 mg) reduces the combined endpoint of cardiovascular mortality, non-fatal myocardial infarction or non-fatal stroke (time to first event). The first secondary endpoint is all-cause mortality.Methods: CORONA is a randomized, double-blind, placebo-controlled trial. Briefly, men and women, aged >= 60 years with chronic symptomatic systolic heart failure of ischemic aetiology and ejection fraction